d*8
2 楼
好消息还是坏消息？
Amarin (AMRN) Says FDA Panel Meeting Will Not Be Scheduled Related to NDA
for AMR101
Amarin (AMRN) Says FDA Panel Meeting Will Not Be Scheduled Related to NDA
for AMR101
d*8
3 楼
February 13, 2012 8:10 AM EST
Amarin Corporation plc (Nasdaq: AMRN) announced today that it was informed
by the U.S. FDA that no advisory committee meeting will be scheduled in
connection with the FDA's review of the NDA seeking approval for the use
AMR101 in the treatment of patients with very high triglycerides (≥500mg/dL
), the company's lead product candidate. The FDA has previously assigned a
Prescription Drug User Fee Act (PDUFA) date of July 26, 2012 for completion
of its review of the AMR101 NDA.
Amarin Corporation plc (Nasdaq: AMRN) announced today that it was informed
by the U.S. FDA that no advisory committee meeting will be scheduled in
connection with the FDA's review of the NDA seeking approval for the use
AMR101 in the treatment of patients with very high triglycerides (≥500mg/dL
), the company's lead product candidate. The FDA has previously assigned a
Prescription Drug User Fee Act (PDUFA) date of July 26, 2012 for completion
of its review of the AMR101 NDA.
d*8
4 楼
市场反映好像是好消息？
K*g
6 楼
这个消息没啥用，庄稼也许会利用一下。
【在 d******8 的大作中提到】
: 好消息还是坏消息？
: Amarin (AMRN) Says FDA Panel Meeting Will Not Be Scheduled Related to NDA
: for AMR101
【在 d******8 的大作中提到】
: 好消息还是坏消息？
: Amarin (AMRN) Says FDA Panel Meeting Will Not Be Scheduled Related to NDA
: for AMR101
K*g
7 楼
飞了，不是废了
相关阅读